Phase I trial of non-aqueous glucagon (CSI-Glucagon) for the prevention of hypoglycaemia in paediatric patients with congenital hyperinsulinism

Trial Profile

Phase I trial of non-aqueous glucagon (CSI-Glucagon) for the prevention of hypoglycaemia in paediatric patients with congenital hyperinsulinism

Planning
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2015

At a glance

  • Drugs Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Adverse reactions
  • Sponsors XERIS Pharmaceuticals
  • Most Recent Events

    • 16 Apr 2015 New trial record
    • 14 Apr 2015 Xeris Pharmaceuticals has been awarded a Phase I-II Fast Track SBIR grant and has received the initial instalment for this trial, which will be conducted at two US children's hospitals, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top